Latest Breaking News On - Caicun zhou - Page 1 : comparemela.com

Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting

SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company…

China
Tongji
Sichuan
Suzhou
Jiangsu
Rhui-zhou
Guangdong
United-states
Hong-kong
Shanghai
Taiwan
Macau

Innovent Announces Data From Pivotal Phase 2 TRUST-I Study Of Taletrectinib(ROS1 Inhibitor) Are Published In The JCO And Reported At 2024 ASCO Annual ...

SAN FRANCISCO, U.S. and SUZHOU, China, June 1, 2024 /PRNewswire/ Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceut

Rhui-zhou
Guangdong
China
Tongji
Sichuan
Suzhou
Jiangsu
Shanghai
Hong-kong
Taiwan
Macau
United-states

Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting

Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Macau
Tongji
Sichuan
China
Chicago
Illinois
United-states
San-francisco
California
Hong-kong
New-york
Taiwan

Evaluating selpercatinib for the treatment of non-small cell lung cancer

Evaluating selpercatinib for the treatment of non-small cell lung cancer
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Brazil
Brazilian
Caicun-zhou
Dor-institute-for-research
Paulo-state-cancer-institute-icesp
New-england-journal
Milena-perez-mak
D-or-institute
Paulo-state-cancer-institute
First-line-selpercatinib

Frontline Serplulimab Plus Chemo Provides Consistent Survival Benefit in Squamous NSCLC

The addition of serplulimab to carboplatin and nab-paclitaxel significantly prolonged survival vs chemotherapy alone when used in the first-line treatment of patients with previously untreated locally advanced or metastatic squamous non–small cell lung cancer.

China
Shanghai
Caicun-zhou
China-national-medical-products-administration
Lung-cancer
Shanghai-pulmonary-hospital
National-medical-products-administration
Nsclc
Serplulimab
Chemotherapy
Survival